相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A 4-item PRECISE-DAPT score for dual antiplatelet therapy duration decision-making
Francesco Costa et al.
AMERICAN HEART JOURNAL (2020)
Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel The ABCD-GENE Score
Dominick J. Angiolillo et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2020)
Ticagrelor With or Without Aspirin After PCI The TWILIGHT Platelet Substudy
Usman Baber et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease
Davide Capodanno et al.
NATURE REVIEWS CARDIOLOGY (2020)
Ticagrelor With or Without Aspirin in High -Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention
Dominick J. Angiolill et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Ticagrelor With or Without Aspirin After Complex Percutaneous Coronary Intervention
George Dangas et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents A Systematic Review and Network Meta-Analysis
Safi U. Khan et al.
CIRCULATION (2020)
The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y12Inhibitor in Patients After Percutaneous Coronary Intervention A Systematic Review and Meta-Analysis
Michelle L. O'Donoghue et al.
CIRCULATION (2020)
Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All-Cause Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention
John D. McClure et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome The TICO Randomized Clinical Trial
Byeong-Keuk Kim et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
The 'Ten Commandments' for the 2020 ESC Guidelines for themanagement of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Jean-Philippe Collet et al.
EUROPEAN HEART JOURNAL (2020)
Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CAD The ASET Pilot Study
Norihiro Kogame et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2020)
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial
Naveen L. Pereira et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Rationale and Design of the Future Optimal Research and Care Evaluation in Patients with Acute Coronary Syndrome (FORCE-ACS) Registry: Towards Personalized Medicine in Daily Clinical Practice
Dean R. P. P. Chan Pin Yin et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic Testing
Francesco Franchi et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2020)
Platelet reactivity patterns in patients treated with dual antiplatelet therapy
Max-Paul Winter et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2019)
Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting
Francesco Costa et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial
Abhinav Sharma et al.
AMERICAN HEART JOURNAL (2019)
Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk
Philip Urban et al.
EUROPEAN HEART JOURNAL (2019)
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention
Dirk Sibbing et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2019)
Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention The SMART-CHOICE Randomized Clinical Trial
Joo-Yong Hahn et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI The STOPDAPT-2 Randomized Clinical Trial
Hirotoshi Watanabe et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial
Deepak L. Bhatt et al.
LANCET (2019)
Ticagrelor with or without Aspirin in High-Risk Patients after PCI
R. Mehran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI
Daniel M. F. Claassens et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Ticagrelor in Patients with Stable Coronary Disease and Diabetes
P. Gabriel Steg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Stroke Outcomes in the COMPASS Trial
Mukul Sharma et al.
CIRCULATION (2019)
The DAPT Score in Sweden Successful Validation, Flawed Interpretation
Robert W. Yeh et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial)
Giuseppe De Luca et al.
EUROINTERVENTION (2019)
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry
Arthur Darmon et al.
EUROPEAN HEART JOURNAL (2018)
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
Marco Valgimigli et al.
EUROPEAN HEART JOURNAL (2018)
Is There Really a Benefit to Net Clinical Benefit in Testing Antithrombotics?
Philippe Gabriel Steg et al.
CIRCULATION (2018)
Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes The PHARMCLO Trial
Francesca Maria Notarangelo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial
Joo-Yong Hahn et al.
LANCET (2018)
Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention
Davide Capodanno et al.
NATURE REVIEWS CARDIOLOGY (2018)
External Validation of the DAPT Score in a Nationwide Population
Peter Ueda et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial
Pascal Vranckx et al.
LANCET (2018)
Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial
Elvin Kedhi et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Duration of antiplatelet therapy after DES implantation: can we trust non-inferiority open-label trials?
Philippe Gabriel Steg et al.
EUROPEAN HEART JOURNAL (2017)
6-Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel)
Romain Didier et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2017)
Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation
Masato Nakamura et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2017)
Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention
Robert W. Yeh et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Tailoring duration of DAPT with risk scores
Davide Capodanno et al.
LANCET (2017)
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials
Francesco Costa et al.
LANCET (2017)
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
E. Magnus Ohman et al.
LANCET (2017)
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial
Dirk Sibbing et al.
LANCET (2017)
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
J. W. Eikelboom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies
Dominick J. Angiolillo et al.
CIRCULATION (2017)
Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent Randomized Substudy of the I-LOVE-IT 2 Trial
Yaling Han et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2016)
6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation The IVUS-XPL Randomized Clinical Trial
Sung-Jin Hong et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2016)
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention
Robert W. Yeh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI
Gennaro Giustino et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease
John A. Bittl et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents Risk Scores From PARIS
Usman Baber et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease
Glenn N. Levine et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial
Guillaume Cayla et al.
LANCET (2016)
Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention
Daniel Aradi et al.
EUROPEAN HEART JOURNAL (2015)
ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting
Stefanie Schulz-Schuepke et al.
EUROPEAN HEART JOURNAL (2015)
Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials
Tullio Palmerini et al.
LANCET (2015)
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
Marc P. Bonaca et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials
Eliano Pio Navarese et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials
Eliano Pio Navarese et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation A Randomized, Controlled Trial
Cheol Whan Lee et al.
CIRCULATION (2014)
Biolimus-Eluting Stents With Biodegradable Polymer Versus Bare-Metal Stents in Acute Myocardial Infarction Two-Year Clinical Results of the COMFORTABLE AMI Trial
Lorenz Raeber et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2014)
Second-Generation Drug-Eluting Stent Implantation Followed by 6-Versus 12-Month Dual Antiplatelet Therapy The SECURITY Randomized Clinical Trial
Antonio Colombo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial
Jean-Philippe Collet et al.
LANCET (2014)
Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
Laura Mauri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY)
Marco Valgimigli et al.
EUROPEAN HEART JOURNAL (2013)
Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: A randomized control trial
Xiang Xie et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Risk of Stent Thrombosis Among Bare-Metal Stents, First-Generation Drug-Eluting Stents, and Second-Generation Drug-Eluting Stents Results From a Registry of 18,334 Patients
Tomohisa Tada et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2013)
Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) Randomized, Multicenter Study
Hyeon-Cheol Gwon et al.
CIRCULATION (2012)
Very Late Coronary Stent Thrombosis of a Newer-Generation Everolimus-Eluting Stent Compared With Early-Generation Drug-Eluting Stents A Prospective Cohort Study
Lorenz Raeber et al.
CIRCULATION (2012)
A New Strategy for Discontinuation of Dual Antiplatelet Therapy The RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)
Byeong-Keuk Kim et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI A Meta-analysis
Jessica L. Mega et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
分享论文
